DME
Novartis eye treatment for diabetics shows positive results in Phase III trial
May 4, 2021Manufacturing and Production DME, Novartis, diabetic macular edema, macular edema, pharma, pharma news
Novartis’ Beovu treatment for diabetic macular edema (DME) – an eye condition that can cause blindness – has shown positive …
FDA clears Roche eye drug
February 9, 2015Sales and Marketing AMD, DME, FDA, Lucentis, Retina, Roche, eyes, ranibizumab
The US Food and Drug Administration has shown Roche’s eye-condition drug Lucentis the green light to treat patients with diabetic …
Bayer submits Eylea in EU for DME
November 8, 2013Sales and Marketing Bayer, DME, EMA, Eylea, FDA
Bayer HealthCare is seeking to extend the licence of its VEGF Trap-Eye, which is already marketed as Eylea in various …
Eylea trial boost in DME
August 7, 2013Research and Development, Sales and Marketing Bayer, DME, Eylea, regenenron
The rival treatment to Novartis’ Lucentis has posted encouraging new study results in patients with diabetic macular oedema (DME). In …
Lucentis boosted by diabetic vision study
May 24, 2010Research and Development, Sales and Marketing AMD, DME, Lucentis, Novartis
A phase III trial of Novartis’ ranibizumab has shown it to be superior at promoting vision gain in patients with …
Latest content
FibroFind appoints Lee Borthwick as CEO
July 21, 2026
